Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

Avoid coadministration of BRAFTOVI with drugs known to prolong QT/QTc interval. View the full Prescribing Information. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new ...

Avoid coadministration of BRAFTOVI with drugs known to prolong QT/QTc interval. View the full Prescribing Information. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in ...

But the downside of approving so many drugs with so few hurdles is now clear: Many don’t prolong life at all, or do so only modestly, with problematic side effects. Indeed, fewer than half of ...

However, this was largely not reiterated in the case report literature where 11 cases of PR interval prolongation ... underappreciated concurrent drug use, and an inaccurate representation ...

Combining two cancer drugs has been found to prolong the lifespan of mice—and may help humans age better. An international team of researchers analyzed the impact of rapamycin and trametinib on ...

The drugs rapamycin and trametinib given together ... dose and route of administration of trametinib to maximise its life-prolonging effects while minimising unwanted side effects.

Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the ...

Videos available at [ Key points A 94-year-old man with parkinsonism, followed in our geriatric medicine clinic, presented for routine follow-up, during which his wife reported that he had a ...

Kounis syndrome is a ubiquitous disease affecting individuals of any age, which can complicate many conditions and explain many clinical conundrums. [57,96,97] We anticipate that more unexplained ...

Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston (S.K., L.G., A.K.). Department of Biosciences, Rice ...